06 September 2018
A new report by visiongain predicts that Novartis (including subsidiary Alcon) will remain the leading ophthalmic company to 2020. This forecast and others appear in Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026, published in May 2016. Visiongain is a business information provider based in London, UK.
The Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026 report examines the current and future trends for companies in the ophthalmic drugs market.
In 2013, the World Health Organization (WHO) estimated the number of people with visual impairment at 285 million, of which 39 million were blind and 246 million had low vision. Blindness and visual impairment disproportionately affect older people; for example, 82% of all blind people are aged 50 years or older. This means that with a burgeoning elderly population globally, the number of people affected by visual impairment is set to increase rapidly.
The ophthalmic drugs market consists of those pharmaceuticals, both prescription and over-the-counter or OTC, which address the diseases and eye conditions that lead to visual impairment, as well as eye conditions of importance for other reasons. There is a greater impact of eye disease in developing countries including the emerging markets of China and India. This makes understanding the ophthalmic drugs market, the leading companies in the market and the opportunities available crucial for all those in fields related to the sector.
In this report, there are analyses of the current leading players in the ophthalmic drugs market, with 10-year ophthalmic drug revenue forecasts. Also given is a breakdown of each company’s leading products, leading pipeline candidates and recent merger & acquisition information, with an analysis of news that may influence the course of the company. Analyses of 21 companies with smaller ophthalmic drug portfolios and promising pipeline candidates which may enter the market over the forecast period are also included.
In this report, we also examine the sales of a wide range of ophthalmic drugs in the following submarkets: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs and Dry Eye Drugs. An analysis of 17 major drugs, with 10-year forecasts and upcoming pipeline candidates in the sector are also included for all of the major submarkets.
Matteo Bianchi, a pharmaceutical and medical devices industry analyst in visiongain, said: “Successful harnessing of growth opportunities in the ophthalmic drugs market from 2016 to 2026 will depend upon the successful development of novel drugs that address multiple aspects of ocular diseases; hence there are a number of combination therapies in the pipeline. There are also several areas of unmet clinical need, most notably in glaucoma, dry AMD and dry eye disease. If a drug candidate with significant disease-modifying properties enters one of these markets over the forecast period, it has the potential to achieve blockbuster status rapidly, as was seen in the wet AMD space with the release of Lucentis. In addition, there is a growing demand for novel delivery methods for ocular drugs and several promising technologies that may change the shape of the market towards the second half of the forecast period.”
Visiongain’s report provides revenue forecasts to 2026 for the ophthalmic drugs market and its leading submarkets, drugs and companies. The report discusses leading companies which hold significant shares of the market in depth. These companies include Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju and Alcon. Visiongain’s report also discusses key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.
Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on firstname.lastname@example.org
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.